Clearmind Medicine Inc. (CMNDF)

OTCMKTS: CMNDF · Delayed Price · USD
0.210
-0.000 (-0.05%)
Sep 28, 2022 4:00 PM EDT - Market open
-0.05%
Market Cap 8.31M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 39.59M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 0.210
Day's Range n/a
52-Week Range 0.050 - 0.730
Beta 1.39
Analysts n/a
Price Target n/a
Earnings Date n/a

About CMNDF

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada. [Read more...]

Industry Biotechnology
Founded 2017
Country United States
Stock Exchange OTCMKTS
Ticker Symbol CMNDF
Full Company Profile

News

Clearmind Announces Notice of Proposed Stock Consolidation

VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development o...

1 week ago - GlobeNewsWire

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.

2 weeks ago - GlobeNewsWire

Clearmind Medicine Announces Share-Based Payment for one of the Company's Consultants

VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "C ompany"), a biotech company focused on discovery and development ...

2 weeks ago - GlobeNewsWire

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI

1 month ago - GlobeNewsWire

Yale's Department of Psychiatry Chair to Join Clearmind Medicine

Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board

3 months ago - GlobeNewsWire

Clearmind Medicine Appoints New Chief Financial Officer

VANCOUVER, June 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of nov...

3 months ago - GlobeNewsWire

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

The patent was granted by India's Office of the Controller-General of Patents, Designs and Trademarks

4 months ago - GlobeNewsWire

Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder

Clearmind aims to initiate clinical trials with CMND-100 by year ' s end

4 months ago - GlobeNewsWire

Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption

4 months ago - GlobeNewsWire

Clearmind Announces Pre-IND Meeting Date with FDA

Clearmind aims to initiate clinical trials with CMND-100 by year' s end

4 months ago - GlobeNewsWire

Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals

Prof . Schütz' main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses ; Prof. Weiser specializes in psychiatric disorders such ...

4 months ago - GlobeNewsWire

Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...

6 months ago - GlobeNewsWire

Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 on Thursday, March 24th

Toronto, Ontario--(Newsfile Corp. - March 23, 2022) - Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on ...

6 months ago - Newsfile Corp

Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration

The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties.

6 months ago - GlobeNewsWire

Clearmind Medicine announces Share-Based Compensation Plan

TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery ...

7 months ago - GlobeNewsWire

Clearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)

Picture1TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the di...

8 months ago - GlobeNewsWire

Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event...

A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development

8 months ago - GlobeNewsWire

Clearmind Medicine Engages the Independent Trading Group as a Market Maker and Thunder11 as a PR Agency

TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...

8 months ago - GlobeNewsWire

Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event

The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances"

8 months ago - GlobeNewsWire

Clearmind Medicine Strengthens Presence in North America with New Senior Appointments

Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strat...

8 months ago - GlobeNewsWire